Market Cap 209.62M
Revenue (ttm) 16.15M
Net Income (ttm) -77.33M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -478.82%
Debt to Equity Ratio 0.00
Volume 315,700
Avg Vol 816,020
Day's Range N/A - N/A
Shares Out 62.02M
Stochastic %K 44%
Beta 1.33
Analysts Strong Sell
Price Target $6.00

Company Profile

Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 cl...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 453 3596
Address:
321 Harrison Avenue, 11th Floor, Suite 1, Boston, United States
biohuntress
biohuntress Oct. 22 at 3:11 PM
$PYXS ESMO- Key Findings from the Presentations Mechanism of Action: MICVO employs a unique extracellular-cleaving method, differing from traditional ADCs, which usually target cell surfaces and internalize inside the cells. Therapeutic Benefits: Direct Tumor Cell Killing: Evidence showed that MICVO directly affects tumor cells. Bystander Killing: The drug aids in killing adjacent cancer cells. Immunogenic Cell Death: Findings highlighted evidence that MICVO activates immune responses against tumors. Clinical Observations: Notable reductions were observed in circulating tumor DNA (ctDNA) in the majority of samples assessed, particularly in head and neck squamous cell carcinoma (HNSCC) cases. Pyxis Oncology's presence at ESMO 2025 marks a critical moment in expanding the understanding and application of MICVO in oncology.
1 · Reply
SaluteYourShorts
SaluteYourShorts Oct. 21 at 3:06 PM
$PYXS heating up again ... still in it
0 · Reply
Stockprofiler
Stockprofiler Oct. 20 at 5:48 PM
$CRDL Zacks Industry Outlook Highlights Akebia Therapeutics, Ironwood Pharmaceuticals, Pyxis Oncology, Cardiol Therapeutics and Plus Therapeutics October 15, 2025 — @ZacksResearch For Immediate Release Chicago, IL – October 15, 2025 – Zacks Equity Research discusses Akebia Therapeutics $AKBA, Ironwood Pharmaceuticals $IRWD, Pyxis Oncology $PYXS, Cardiol Therapeutics $CRDL and Plus Therapeutics $PSTV. Industry: Drugs (non-Big Pharma) Link: https://zacks.com/commentary/2767977/5-small-drug-stocks-to-buy-as-the-industry-shows-some-recovery
0 · Reply
Hawaiiansurf1
Hawaiiansurf1 Oct. 19 at 3:10 AM
$PYXS Data is better than CRBP. 50% ORR and 100% stopping all progression. Waiting on bigger Sample Size. Will SKYROCKET with upcoming results.
1 · Reply
Bainv
Bainv Oct. 18 at 6:24 PM
$PYXS CRBP's data bad for PYXS? need to have better ORR.
0 · Reply
FinJay
FinJay Oct. 15 at 1:59 PM
🚨 5 Short Squeeze Stocks About to Rip! 🔥 Massive Naked Shorting Exposed 👀 Big moves could be coming soon — don’t miss this breakdown ⬇️ $CRML $BJDX $ELBM $PYXS $DPRO 📺 https://youtu.be/1cmFwhOhgt4
0 · Reply
St0ckman691
St0ckman691 Oct. 14 at 5:11 PM
$CRDL makes the list of 5 Small Drug Stocks to Buy as the Industry Shows Some Recovery: $AKBA $IRWD $PYXS $PSTV https://finance.yahoo.com/news/5-small-drug-stocks-buy-145700720.html
1 · Reply
Power2k
Power2k Oct. 14 at 3:23 PM
$PYXS $GMAB acquired $MRUS for 8B mostly due to Merus' promising Head & Neck cancer (HNSCC) trial data. Pyxis has a matched or even a bit superior HNSCC data than Merus', and it sits only at 200M cap. Extremely undervalued.
0 · Reply
biohuntress
biohuntress Oct. 13 at 8:09 PM
$PYXS ESMO https://ir.pyxisoncology.com/news-releases/news-release-details/pyxis-oncology-present-translational-data-and-key-biology
0 · Reply
SaluteYourShorts
SaluteYourShorts Oct. 13 at 4:50 PM
$PYXS waking up
0 · Reply
Latest News on PYXS
Pyxis Oncology's Cancer Drug Progress Stirs Analyst Concerns

Nov 21, 2024, 9:18 AM EST - 1 year ago

Pyxis Oncology's Cancer Drug Progress Stirs Analyst Concerns


Moment Of Truth Approaches For Pyxis Oncology

Sep 13, 2024, 7:08 AM EDT - 1 year ago

Moment Of Truth Approaches For Pyxis Oncology


Pyxis Oncology Successfully Completes Acquisition of Apexigen

Aug 23, 2023, 8:35 AM EDT - 2 years ago

Pyxis Oncology Successfully Completes Acquisition of Apexigen


Pyxis: Unique ADC Approach With A Catalyst In Late 2023

Jun 15, 2023, 8:20 AM EDT - 2 years ago

Pyxis: Unique ADC Approach With A Catalyst In Late 2023


Pyxis Oncology Advances PYX-106 and PYX-201 Clinical Programs

May 30, 2023, 8:30 AM EDT - 2 years ago

Pyxis Oncology Advances PYX-106 and PYX-201 Clinical Programs


Pyxis Oncology to Acquire Apexigen

May 24, 2023, 6:45 AM EDT - 2 years ago

Pyxis Oncology to Acquire Apexigen


Pyxis Oncology: Cashed Up And Entering The Clinic

Mar 27, 2023, 7:32 AM EDT - 2 years ago

Pyxis Oncology: Cashed Up And Entering The Clinic


biohuntress
biohuntress Oct. 22 at 3:11 PM
$PYXS ESMO- Key Findings from the Presentations Mechanism of Action: MICVO employs a unique extracellular-cleaving method, differing from traditional ADCs, which usually target cell surfaces and internalize inside the cells. Therapeutic Benefits: Direct Tumor Cell Killing: Evidence showed that MICVO directly affects tumor cells. Bystander Killing: The drug aids in killing adjacent cancer cells. Immunogenic Cell Death: Findings highlighted evidence that MICVO activates immune responses against tumors. Clinical Observations: Notable reductions were observed in circulating tumor DNA (ctDNA) in the majority of samples assessed, particularly in head and neck squamous cell carcinoma (HNSCC) cases. Pyxis Oncology's presence at ESMO 2025 marks a critical moment in expanding the understanding and application of MICVO in oncology.
1 · Reply
SaluteYourShorts
SaluteYourShorts Oct. 21 at 3:06 PM
$PYXS heating up again ... still in it
0 · Reply
Stockprofiler
Stockprofiler Oct. 20 at 5:48 PM
$CRDL Zacks Industry Outlook Highlights Akebia Therapeutics, Ironwood Pharmaceuticals, Pyxis Oncology, Cardiol Therapeutics and Plus Therapeutics October 15, 2025 — @ZacksResearch For Immediate Release Chicago, IL – October 15, 2025 – Zacks Equity Research discusses Akebia Therapeutics $AKBA, Ironwood Pharmaceuticals $IRWD, Pyxis Oncology $PYXS, Cardiol Therapeutics $CRDL and Plus Therapeutics $PSTV. Industry: Drugs (non-Big Pharma) Link: https://zacks.com/commentary/2767977/5-small-drug-stocks-to-buy-as-the-industry-shows-some-recovery
0 · Reply
Hawaiiansurf1
Hawaiiansurf1 Oct. 19 at 3:10 AM
$PYXS Data is better than CRBP. 50% ORR and 100% stopping all progression. Waiting on bigger Sample Size. Will SKYROCKET with upcoming results.
1 · Reply
Bainv
Bainv Oct. 18 at 6:24 PM
$PYXS CRBP's data bad for PYXS? need to have better ORR.
0 · Reply
FinJay
FinJay Oct. 15 at 1:59 PM
🚨 5 Short Squeeze Stocks About to Rip! 🔥 Massive Naked Shorting Exposed 👀 Big moves could be coming soon — don’t miss this breakdown ⬇️ $CRML $BJDX $ELBM $PYXS $DPRO 📺 https://youtu.be/1cmFwhOhgt4
0 · Reply
St0ckman691
St0ckman691 Oct. 14 at 5:11 PM
$CRDL makes the list of 5 Small Drug Stocks to Buy as the Industry Shows Some Recovery: $AKBA $IRWD $PYXS $PSTV https://finance.yahoo.com/news/5-small-drug-stocks-buy-145700720.html
1 · Reply
Power2k
Power2k Oct. 14 at 3:23 PM
$PYXS $GMAB acquired $MRUS for 8B mostly due to Merus' promising Head & Neck cancer (HNSCC) trial data. Pyxis has a matched or even a bit superior HNSCC data than Merus', and it sits only at 200M cap. Extremely undervalued.
0 · Reply
biohuntress
biohuntress Oct. 13 at 8:09 PM
$PYXS ESMO https://ir.pyxisoncology.com/news-releases/news-release-details/pyxis-oncology-present-translational-data-and-key-biology
0 · Reply
SaluteYourShorts
SaluteYourShorts Oct. 13 at 4:50 PM
$PYXS waking up
0 · Reply
Relee187200
Relee187200 Oct. 13 at 3:09 PM
$PYXS What happened?!
2 · Reply
Bullbear1010101
Bullbear1010101 Oct. 10 at 10:57 PM
$PYXS looks stable even with market down around 3 percent ..lost about .12 only today too high for me to rebuy
0 · Reply
smoketuna
smoketuna Oct. 10 at 10:21 AM
$PYXS 83% with 🎯 TunaSignal.ai score! while price $2.X.14 - Catch the Big Movers Before They Break Out - Powered by AI
0 · Reply
stockchacing
stockchacing Oct. 10 at 5:05 AM
$PYXS amazing performance 😎! Next one to skyrocket will be $SLS ! FCK Cancer!!
0 · Reply
StockScanners
StockScanners Oct. 10 at 2:17 AM
$PYXS reached 3.93. come on team lets go!
0 · Reply
StockScanners
StockScanners Oct. 10 at 1:45 AM
$PYXS keep watch if this holds above 3.60
0 · Reply
JacksofAmerica
JacksofAmerica Oct. 10 at 12:19 AM
$PYXS made a decent purchase of this stock at $1.07 i has no idea it would jump this quickly. Wish i put more down 😄
0 · Reply
stocksrtoohard
stocksrtoohard Oct. 9 at 10:55 PM
$PYXS was pretty close to one of the best trades ive ever made off gut instinct and basic price action that ive studied for 2-3y+. here is the timeline; inverted h&s on 30m/1h/4h breakout and hold of $2.55 (harsh retests on the way). been clear break since and may be re-entering to a pos. again soon if a pullback presents itself properly (drop some pos placement if any). took my final pay on pos. at $3.10-3.20 (~450% gained in total). didn’t want to risk little volume not being able to push through the gap. hope everyone made some bread and continues to if she keeps ripping 🤘🏽
0 · Reply
Hawaiiansurf1
Hawaiiansurf1 Oct. 9 at 9:49 PM
$PYXS Genmab bought Pyxix competition Merus for 8 Billion ($97 share). Pyxis has superior MOA (Mechanism of Action). We skyrocket with Good results!
0 · Reply
IntraTrades
IntraTrades Oct. 9 at 9:48 PM
$NUAI 81.41% $JFU 51.62% $PYXS 31.62% $LAES 31.53%
0 · Reply
stockchacing
stockchacing Oct. 9 at 8:03 PM
$SLS normally this stock should be performing like this little one $PYXS ! Really impressive , hope to see the same and better soon for our SLS family! Good night from Switzerland!
0 · Reply
SaluteYourShorts
SaluteYourShorts Oct. 9 at 7:55 PM
$FLUX $PYXS $LAES LFG BABY
0 · Reply